A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis

Jeffrey V. Lazarus; Paul Brennan; Henry E Mark; William  Alazawi; Alina M. Allen; Christopher D Byrne; Laurent Castera; Cyrielle Caussy; Kenneth Cusi; Martin M.  Grajower; Christopher J.  Kopka; Jo  Massoels; Michael Roden; C. Wendy Spearman; Frank Tacke; Vincent  Wai-Sun Wong; Mazen  Noureddin

doi:10.1016/j.lanepe.2025.101320

A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis

Jeffrey V. Lazarus (Lead / Corresponding author), Paul Brennan, Henry E Mark, William Alazawi, Alina M. Allen, Christopher D Byrne, Laurent Castera, Cyrielle Caussy, Kenneth Cusi, Martin M. Grajower, Christopher J. Kopka, Jo Massoels, Michael Roden, C. Wendy Spearman, Frank Tacke, Vincent Wai-Sun Wong, Mazen Noureddin

Respiratory Medicine and Gastroenterology

Research output: Contribution to journal › Review article › peer-review

3 Downloads (Pure)

Abstract

Metabolic dysfunction-associated steatohepatitis (MASH) is an increasingly important contributor to morbidity and mortality. Little emphasis has been placed on its timely diagnosis and interventions to prevent adverse disease outcomes. The principal determinant of MASH outcomes is the liver fibrosis stage. The prevalence of MASH is higher among people living with obesity and/or type 2 diabetes, with MASH with moderate to advanced fibrosis affecting one in six adults. Delivering a paradigm shift in MASH diagnosis in the four countries studied will require an expansion of community-based diagnostic capability that will also foster prevention efforts and provide opportunities for treatment and care.

Original language	English
Article number	101320
Number of pages	9
Journal	The Lancet Regional Health - Europe
Early online date	4 Jun 2025
DOIs	https://doi.org/10.1016/j.lanepe.2025.101320
Publication status	E-pub ahead of print - 4 Jun 2025

Keywords

MASLD
MASH
Diagnostic rate
Health policy
Health systems
Public health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.lanepe.2025.101320Licence: CC BY

Final Published VersionFinal published version, 811 KBLicence: CC BY

Cite this

Lazarus, J. V., Brennan, P., Mark, H. E., Alazawi, W., Allen, A. M., Byrne, C. D., Castera, L., Caussy, C., Cusi, K., Grajower, M. M., Kopka, C. J., Massoels, J., Roden, M., Spearman, C. W., Tacke, F., Wai-Sun Wong, V., & Noureddin, M. (2025). A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis. The Lancet Regional Health - Europe, Article 101320. Advance online publication. https://doi.org/10.1016/j.lanepe.2025.101320

@article{13ac7efad7fe48fda694e7be07629bd8,

title = "A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis",

abstract = "Metabolic dysfunction-associated steatohepatitis (MASH) is an increasingly important contributor to morbidity and mortality. Little emphasis has been placed on its timely diagnosis and interventions to prevent adverse disease outcomes. The principal determinant of MASH outcomes is the liver fibrosis stage. The prevalence of MASH is higher among people living with obesity and/or type 2 diabetes, with MASH with moderate to advanced fibrosis affecting one in six adults. Delivering a paradigm shift in MASH diagnosis in the four countries studied will require an expansion of community-based diagnostic capability that will also foster prevention efforts and provide opportunities for treatment and care.",

keywords = "MASLD, MASH, Diagnostic rate, Health policy, Health systems, Public health",

author = "Lazarus, {Jeffrey V.} and Paul Brennan and Mark, {Henry E} and William Alazawi and Allen, {Alina M.} and Byrne, {Christopher D} and Laurent Castera and Cyrielle Caussy and Kenneth Cusi and Grajower, {Martin M.} and Kopka, {Christopher J.} and Jo Massoels and Michael Roden and Spearman, {C. Wendy} and Frank Tacke and {Wai-Sun Wong}, Vincent and Mazen Noureddin",

note = "Publisher Copyright: {\textcopyright} 2025 The Author(s)",

year = "2025",

month = jun,

day = "4",

doi = "10.1016/j.lanepe.2025.101320",

language = "English",

journal = "The Lancet Regional Health - Europe",

issn = "2666-7762",

publisher = "Elsevier",

}

Lazarus, JV, Brennan, P, Mark, HE, Alazawi, W, Allen, AM, Byrne, CD, Castera, L, Caussy, C, Cusi, K, Grajower, MM, Kopka, CJ, Massoels, J, Roden, M, Spearman, CW, Tacke, F, Wai-Sun Wong, V & Noureddin, M 2025, 'A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis', The Lancet Regional Health - Europe. https://doi.org/10.1016/j.lanepe.2025.101320

TY - JOUR

T1 - A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis

AU - Lazarus, Jeffrey V.

AU - Brennan, Paul

AU - Mark, Henry E

AU - Alazawi, William

AU - Allen, Alina M.

AU - Byrne, Christopher D

AU - Castera, Laurent

AU - Caussy, Cyrielle

AU - Cusi, Kenneth

AU - Grajower, Martin M.

AU - Kopka, Christopher J.

AU - Massoels, Jo

AU - Roden, Michael

AU - Spearman, C. Wendy

AU - Tacke, Frank

AU - Wai-Sun Wong, Vincent

AU - Noureddin, Mazen

PY - 2025/6/4

Y1 - 2025/6/4

N2 - Metabolic dysfunction-associated steatohepatitis (MASH) is an increasingly important contributor to morbidity and mortality. Little emphasis has been placed on its timely diagnosis and interventions to prevent adverse disease outcomes. The principal determinant of MASH outcomes is the liver fibrosis stage. The prevalence of MASH is higher among people living with obesity and/or type 2 diabetes, with MASH with moderate to advanced fibrosis affecting one in six adults. Delivering a paradigm shift in MASH diagnosis in the four countries studied will require an expansion of community-based diagnostic capability that will also foster prevention efforts and provide opportunities for treatment and care.

AB - Metabolic dysfunction-associated steatohepatitis (MASH) is an increasingly important contributor to morbidity and mortality. Little emphasis has been placed on its timely diagnosis and interventions to prevent adverse disease outcomes. The principal determinant of MASH outcomes is the liver fibrosis stage. The prevalence of MASH is higher among people living with obesity and/or type 2 diabetes, with MASH with moderate to advanced fibrosis affecting one in six adults. Delivering a paradigm shift in MASH diagnosis in the four countries studied will require an expansion of community-based diagnostic capability that will also foster prevention efforts and provide opportunities for treatment and care.

KW - MASLD

KW - MASH

KW - Diagnostic rate

KW - Health policy

KW - Health systems

KW - Public health

UR - http://www.scopus.com/inward/record.url?scp=105007301450&partnerID=8YFLogxK

U2 - 10.1016/j.lanepe.2025.101320

DO - 10.1016/j.lanepe.2025.101320

M3 - Review article

SN - 2666-7762

JO - The Lancet Regional Health - Europe

JF - The Lancet Regional Health - Europe

M1 - 101320

ER -

A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this